...
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway
【24h】

Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway

机译:利拉鲁肽通过增强线粒体结构并通过SIRT1 / SIRT3-FOXO3a途径促进自噬来改善非酒精性脂肪肝疾病

获取原文
获取原文并翻译 | 示例
           

摘要

AimOverwhelming oxidative stress is implicated as crucial in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Liraglutide, a well-established antidiabetes drug, was recently reported to ameliorate NAFLD with an elusive mechanism. We used a mouse model to examine whether liraglutide could ameliorate NAFLD and explored the possible mechanisms.
机译:目的:在非酒精性脂肪肝疾病(NAFLD)的发病机理中,压倒性氧化应激至关重要。利拉鲁肽是一种公认​​的抗糖尿病药物,最近有报道以一种难以捉摸的机制改善了NAFLD。我们使用小鼠模型检查了利拉鲁肽是否可以改善NAFLD,并探讨了可能的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号